SBP Group CEO Eric Tse discusses his outlook for China's healthcare sector and how one of China's old-guard pharmaceutical players aims to transition from generics focused model to drug development. He speaks with Stephen Engle from the sidelines of 'The World Economic Forum's Annual Meeting of the New Champions' in Dalian. (Source: Bloomberg)

Sources tell Bloomberg that SpaceX’s initial public offering is well oversubscribed with multiple institutional investors placing orders for about $10 billion or more of shares. Elon Musk's company is leading a race to list against both OpenAI and Anthropic. The Opening Trade has everything you need to know as markets open across Europe. With analysis you won't find anywhere else, we break down the biggest stories of the day and speak to top guests who have skin in the game. Hosted by Anna Edwards and Tom Mackenzie. (Source: Bloomberg)

GSK Plc is in discussions to purchase cancer treatment maker Nuvalent Inc. for between $9 billion and $10 billion, the Financial Times reported, citing unidentified people familiar with the matter.

GSK Plc’s older respiratory medicines showed lackluster sales in the first quarter, leaving HIV and cancer drugs to drive growth and sending shares into their steepest dive in almost two years.

GSK Plc agreed to buy 35Pharma Inc., a biotech with an early-stage drug for pulmonary hypertension, as the UK pharma giant boosts its pipeline of promising experimental therapies.

GSK Plc agreed to buy Rapt Therapeutics, a US-based biotech developing treatments for patients with inflammatory and immunologic diseases, in a deal valued at $2.2 billion.

AstraZeneca CFO Aradhana Sarin discusses the company's M&A strategy and weight-loss portfolio with Katie Greifeld at the JPMorgan Health-Care Conference in San Francisco. (Source: Bloomberg)